A phase I and pharmacological study of intermittent dosing of PKI166, a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally to patients with advanced cancer.

被引：0
|
作者：
Hoekstra, R
Dumez, H
Eskens, F
Sizer, K
Cohen, P
Ravera, G
Verweij, J
Van Oosterom, A
机构：
[1] Univ Rotterdam Hosp, Rotterdam, Netherlands
[2] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[3] Novartis Pharma, E Hanover, NJ USA
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
585
引用
收藏
页码：3771S / 3771S
页数：1
相关论文
共 50 条
  • [1] Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
    Hoekstra, R
    Dumez, H
    Eskens, FALM
    van der Gaast, A
    Planting, AST
    de Heus, G
    Sizer, KC
    Ravera, C
    Vaidyanathan, S
    Bucana, C
    Fidler, IJ
    van Oosterom, AT
    Verweij, J
    CLINICAL CANCER RESEARCH, 2005, 11 (19) : 6908 - 6915
  • [2] A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers.
    Papadimitrakopoulou, VA
    Murren, JR
    Fidler, IJ
    Bucana, CD
    Sizer, K
    Cohen, P
    Ravera, C
    Abbruzzese, JL
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3708S - 3708S
  • [3] Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations
    Moran, Teresa
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : 3330 - 3336
  • [4] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
    Hidalgo, M
    Siu, LL
    Nemunaitis, J
    Rizzo, J
    Hammond, LA
    Takimoto, C
    Eckhardt, SG
    Tolcher, A
    Britten, CD
    Denis, L
    Ferrante, K
    Von Hoff, DD
    Silberman, S
    Rowinsky, EK
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3267 - 3279
  • [5] Novel mutations in tyrosine kinase domain of epidermal growth factor receptor in prostate cancer.
    Douglas, D.
    Zhong, H.
    Ro, J.
    Oddoux, C.
    Pincus, M.
    Satagopan, J.
    Gerald, W.
    Schei, H.
    Lee, P.
    Osman, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 244S - 244S
  • [6] Hepatic transport of PKI166, an epidermal growth factor receptor kinase inhibitor of the pyrrolo-pyrimidine class, and its main metabolite, ACU154
    Takada, T
    Weiss, HM
    Kretz, O
    Gross, G
    Sugiyama, Y
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (11) : 1272 - 1278
  • [7] A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
    Jazieh, Khalid
    Molina, Julian
    Allred, Jacob
    Yin, Jun
    Reid, Joel
    Goetz, Matthew
    Lim, Vun-Sin
    Kaufmann, Scott H.
    Adjei, Alex
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 307 - 314
  • [8] A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
    Khalid Jazieh
    Julian Molina
    Jacob Allred
    Jun Yin
    Joel Reid
    Matthew Goetz
    Vun-Sin Lim
    Scott H. Kaufmann
    Alex Adjei
    Investigational New Drugs, 2019, 37 : 307 - 314
  • [9] The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
    Wu, Zhen
    Dai, Yu
    Chen, Liang-An
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 8835 - 8843
  • [10] Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer
    Wang Han-ping
    Zhang Li
    Wang Yin-xiang
    Tan Fen-lai
    Xia Ying
    Ren Guan-jun
    Hu Pei
    Jiang Ji
    Wang Meng-zhao
    Xiao Yi
    CHINESE MEDICAL JOURNAL, 2011, 124 (13) : 1933 - 1938
12345